SCHEMBL6242541

SCHEMBL6242541

COc1cccc(CNc2nc(Nc3ccc4[nH]cc(C5=CCNCC5)c4c3)ncc2Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ HTR1D P28221 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ BRCA1 P38398 1/20 0.50
▸ HTR6 P50406 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ IGF1R P08069 3/20 0.45
▸ NTRK1 P04629 2/20 0.45
▸ PTK2 Q05397 2/20 0.42
▸ STAT6 P42226 1/20 0.42
▸ HTR1A P08908 4/20 0.42
▸ DRD2 P14416 4/20 0.42
▸ JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6212762 0.93 ALDH1A1 (0.49) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6211382 0.92 HTR6 (0.52) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6241718 0.91 PRKCD (0.47) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6209598 0.91 PTK2 (0.44) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6212141 0.90 KDM4E (0.43) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6212597 0.89 NTRK1 (0.49) NTRK1PTK2
SCHEMBL6236688 0.88 PTK2 (0.42) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6241707 0.88 KDM4E (0.43) KDM4EMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL5215707 0.87 PTK2 (0.60) NTRK1PTK2JAK3
SCHEMBL5213222 0.87 PTK2 (0.48) KDM4EMEN1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 KDM4E 2081/4885MEN1 365/4885ALDH1A1 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback